Jazz Pharmaceuticals Enters Material Definitive Agreement
Ticker: JAZZ · Form: 8-K · Filed: Nov 26, 2024 · CIK: 1232524
| Field | Detail |
|---|---|
| Company | Jazz Pharmaceuticals PLC (JAZZ) |
| Form Type | 8-K |
| Filed Date | Nov 26, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001, $500 million, $885 million, $500,000,000, $50 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-obligation
TL;DR
Jazz Pharma just signed a big deal, expect new financial obligations.
AI Summary
On November 26, 2024, Jazz Pharmaceuticals plc entered into a material definitive agreement. This filing also indicates the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement for the registrant. The filing includes financial statements and exhibits related to these events.
Why It Matters
This filing signals a significant new agreement for Jazz Pharmaceuticals, potentially impacting its financial obligations and future business operations.
Risk Assessment
Risk Level: medium — Entering into material definitive agreements and creating financial obligations can introduce new risks related to performance, financing, and market conditions.
Key Players & Entities
- Jazz Pharmaceuticals plc (company) — Registrant
- November 26, 2024 (date) — Date of Report
FAQ
What type of material definitive agreement did Jazz Pharmaceuticals enter into?
The filing does not specify the exact nature of the material definitive agreement, only that one was entered into on November 26, 2024.
What are the specific financial obligations created by this filing?
The filing indicates the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement, but the specific details and amounts are not provided in this summary.
Are there any new financial statements included with this filing?
Yes, the filing states that financial statements and exhibits are included.
What is the company's fiscal year end?
The company's fiscal year end is December 31.
Where is Jazz Pharmaceuticals plc incorporated?
Jazz Pharmaceuticals plc is incorporated in Ireland.
Filing Stats: 1,531 words · 6 min read · ~5 pages · Grade level 12.2 · Accepted 2024-11-26 17:02:00
Key Financial Figures
- $0.0001 — istered Ordinary shares, nominal value $0.0001 per share JAZZ The Nasdaq Stock Mar
- $500 million — initial revolving credit facility from $500 million to $885 million (as amended, the " Revo
- $885 million — ng credit facility from $500 million to $885 million (as amended, the " Revolving Credit Fac
- $500,000,000 — , as of February 4, 2028, (x) more than $500,000,000 of the tranche B-2 dollar term loans un
- $50 million — eralized letters of credit in excess of $50 million are outstanding) under the Revolving Cr
- $500 m — ich the aggregate consideration exceeds $500 million, the maximum first lien secured n
Filing Documents
- d833314d8k.htm (8-K) — 34KB
- d833314dex101.htm (EX-10.1) — 1422KB
- 0001193125-24-266184.txt ( ) — 1909KB
- jazz-20241126.xsd (EX-101.SCH) — 3KB
- jazz-20241126_lab.xml (EX-101.LAB) — 18KB
- jazz-20241126_pre.xml (EX-101.PRE) — 11KB
- d833314d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Amendment No. 3, dated as of November 26, 2024, by and among Jazz Pharmaceuticals Public Limited Company, the other borrowers party thereto, the guarantors party thereto, the lenders and issuing banks party thereto, Bank of America, N.A., as administrative agent, and U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association), as collateral trustee. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY By: /s/ Philip L. Johnson Name: Philip L. Johnson Title: Executive Vice President and Chief Financial Officer Date: November 26, 2024